Nasdaq:PLRX
PLIANT THERAPEUTICS, INC.
A clinical-stage biotech firm leveraging DNA origami technology to develop curative treatments for rare genetic disorders.
Key Metrics
Investment Thesis
Bull Case
Pliant offers exposure to a novel technology platform capable of addressing unmet needs in the rare disease market, which often supports favorable pricing and regulatory incentives. If clinical trials demonstrate proof-of-concept for protein folding correction, the company could unlock substantial value with limited remaining R&D capital required.
Bear Case
The absence of revenue combined with widening losses suggests a high risk of capital depletion if future financing markets tighten or clinical milestones are missed. The heavy reliance on non-operating cash flows and significant accrued expenses indicates potential liquidity pressures as the company scales its research programs.
About PLIANT THERAPEUTICS, INC.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare genetic diseases, primarily utilizing its proprietary DNA origami platform to engineer protein-folding correctors.
Analysis
Management Discussion
Financial performance shows substantial cash burn, with operating expenses reaching $228.4M driven largely by R&D expenditures of $169.3M and general administrative costs of $59.1M. Despite a net loss of $210.3M in the latest period, the company maintained a healthy cash position ending at $72.7M, supported by significant financing cash flows and investment proceeds.
Industry Overview
The rare disease therapeutics sector is characterized by high R&D costs, long development timelines, and reliance on orphan drug exclusivity periods to recoup investments. Biotech firms in this space often trade at high valuations based on pipeline potential rather than current earnings, making them sensitive to interest rate environments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $9.7M | $1.6M | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $9.7M | $1.6M | $0 |
| Operating Expenses | $136.9M | $185.7M | $228.4M |
| Operating Income | $-127.2M | $-184.1M | $-228.4M |
| R&D | $96.9M | $127.8M | $169.3M |
| G&A | $39.9M | $57.9M | $59.1M |
| Stock-Based Comp | $22.6M | $44.5M | $37.6M |
| Depreciation | $1.8M | $1.8M | $2.1M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $3.9M | $22.8M | $18.1M |
| Interest Expense | — | $1.3M | — |
| Pre-Tax Income | $-123.3M | $-161.3M | $-210.3M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-123.3M | $-161.3M | $-210.3M |
| Discontinued Ops | $-21.0K | $0 | $-4.0K |
| Net Income | $-123.3M | $-161.3M | $-210.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-123.3M | $-161.3M | $-210.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $340.3M | $505.5M | $362.3M |
| Cash & Equivalents | $33.7M | $63.2M | $71.2M |
| Marketable Securities | $297.5M | $431.0M | $284.5M |
| Accounts Receivable | $2.0M | $0 | — |
| Prepaid Expenses | $7.1M | $11.3M | $6.5M |
| Other Current Assets | $83.0K | $0 | $0 |
| Long-Term Assets | $10.3M | $6.7M | $34.7M |
| PP&E (Net) | $4.5M | $3.6M | $5.5M |
| Operating Leases | $5.4M | $1.2M | $27.2M |
| Other LT Assets | $394.0K | $1.9M | $1.9M |
| Total Assets | $350.6M | $512.2M | $396.9M |
| Current Liabilities | $23.9M | $28.5M | $33.2M |
| Accounts Payable | $1.6M | $4.5M | $6.0M |
| Current Leases | $2.5M | $1.3M | $542.0K |
| Other Current Liab | $19.9M | $12.5M | $14.4M |
| Long-Term Liabilities | $13.4M | $10.1M | $59.6M |
| LT Operating Leases | $3.4M | $0 | $29.4M |
| Other LT Liab | $9.9M | $10.1M | $30.2M |
| Total Liabilities | $37.3M | $38.6M | $92.9M |
| Shareholders' Equity | $313.3M | $473.6M | $304.1M |
| Retained Earnings | $-338.4M | $-499.7M | $-710.1M |
| AOCI | $-2.0M | $345.0K | $321.0K |
| Total L&E | $350.6M | $512.2M | $396.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-123.3M | $-161.3M | $-210.3M |
| Non-Cash Adjustments | $24.3M | $40.2M | $55.1M |
| Working Capital Changes | $4.4M | $4.8M | $-259.0K |
| Cash from Operations | $-94.6M | $-116.4M | $-155.5M |
| Capital Expenditures | $1.8M | $921.0K | $3.8M |
| Cash from Investing | $-150.2M | $-127.0M | $140.3M |
| Cash from Financing | $226.9M | $274.4M | $23.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-18.0M | $31.0M | $8.0M |
| Beginning Cash | $51.7M | $33.7M | $64.7M |
| Ending Cash | $33.7M | $64.7M | $72.7M |
Frequently Asked Questions
How does PLIANT THERAPEUTICS, INC. make money?
The company operates through a single primary segment focused on orphan drug development, with R&D concentrated in correcting misfolded proteins caused by genetic mutations. Current financials reflect activities centered on Phase 1 and Phase 2 clinical trials rather than commercial sales, evidenced by zero revenue and significant cash burn.
What are the main risks for PLRX?
The company faces high clinical trial risk as success depends on the efficacy of its DNA origami constructs in complex biological environments. Investors must consider significant dilution risks due to negative net income and heavy reliance on external financing given the lack of commercial revenue streams. Regulatory hurdles for novel gene editing or protein therapy platforms may be more stringent than traditional small molecule drugs.
What is PLRX's competitive advantage?
Pliant possesses a unique proprietary platform that uses DNA origami to create precise structural scaffolds for protein correctors, differentiating it from standard CRISPR or antibody-based competitors. The company benefits from a strong balance sheet with over $300M in marketable securities and cash, providing ample runway to advance multiple programs simultaneously.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.